Cargando…

Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects

PURPOSE: The studies reported here aimed to assess the safety and tolerability of cetirizine ophthalmic solution 0.24%, a new topical ophthalmic medication approved by the US Food and Drug Administration for the treatment of ocular itching associated with allergic conjunctivitis. PATIENTS AND METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Malhotra, Ranjan P, Meier, Edward, Torkildsen, Gail, Gomes, Paul J, Jasek, Mark C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387590/ https://www.ncbi.nlm.nih.gov/pubmed/30858690 http://dx.doi.org/10.2147/OPTH.S186092

Ejemplares similares

Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model
por: Meier, Edward J, et al.
Publicado: (2018)

Evaluation of the Effect of Latanoprostene Bunod Ophthalmic Solution, 0.024% in Lowering Intraocular Pressure over 24 h in Healthy Japanese Subjects
por: Araie, Makoto, et al.
Publicado: (2015)

Treatment of allergic conjunctivitis with bepotastine besilate ophthalmic solution 1.5%
por: Bergmann, Mark T, et al.
Publicado: (2014)

Update and clinical utility of alcaftadine ophthalmic solution 0.25% in the treatment of allergic conjunctivitis
por: Chigbu, DeGaulle I, et al.
Publicado: (2015)

Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis
por: McLaurin, Eugene, et al.
Publicado: (2017)

Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model
por: Torkildsen, Gail, et al.
Publicado: (2015)

In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
por: Sheppard, John D., et al.
Publicado: (2018)

Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension
por: Hoy, Sheridan M.
Publicado: (2018)

Bepotastine besilate ophthalmic solution 1.5% for alleviating nasal symptoms in patients with allergic conjunctivitis
por: Cavet, Megan E, et al.
Publicado: (2018)

Comparative study of the ocular efficacy and safety of diclofenac sodium (0.1%) ophthalmic solution with that of ketorolac tromethamine (0.5%) ophthalmic solution in patients with acute seasonal allergic conjunctivitis
por: Dehar, Navdeep, et al.
Publicado: (2012)

Correction to: Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension
por: Hoy, Sheridan M.
Publicado: (2018)

Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy
por: Addis, Victoria M, et al.
Publicado: (2018)

Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates
por: Sanfilippo, Christine M., et al.
Publicado: (2017)

Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open‐angle glaucoma and ocular hypertension
por: Fingeret, Murray, et al.
Publicado: (2019)

Azelastine hydrochloride, a dual-acting anti-inflammatory ophthalmic solution, for treatment of allergic conjunctivitis
por: Williams, Patricia B, et al.
Publicado: (2010)

Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%
por: Greiner, Jack V, et al.
Publicado: (2011)

The Safety of Besifloxacin Ophthalmic Suspension 0.6 % Used Three Times Daily for 7 Days in the Treatment of Bacterial Conjunctivitis
por: Malhotra, Ranjan, et al.
Publicado: (2013)

Clinical use of gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis
por: Cervantes, Lorenzo J, et al.
Publicado: (2011)

Clinical comparison of the efficacy of spirulina platensis and cetirizine for treatment of allergic rhinitis
por: Nourollahian, Morteza, et al.
Publicado: (2020)

Olopatadine ophthalmic solution suppresses substance P release in the conjunctivitis models
por: Tamura, Tadafumi
Publicado: (2012)

Magnetostrictive Properties of Mn(0.70)Zn(0.24)Fe(2.06)O(4) Ferrite
por: Bieńkowski, Adam, et al.
Publicado: (2018)

Allergic conjunctivitis
por: Rathi, Varsha M, et al.
Publicado: (2017)

Cetirizine for the treatment of allergic diseases in children: A systematic review and meta-analysis
por: Zhou, Pengxiang, et al.
Publicado: (2022)

Gatifloxacin Ophthalmic Solution for Treatment of Bacterial Conjunctivitis: Safety, Efficacy and Patient Perspective
por: Schultz, Clyde
Publicado: (2012)

Allergic conjunctivitis in Asia
por: Thong, Bernard Yu-Hor
Publicado: (2017)

Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile
por: Haas, Wolfgang, et al.
Publicado: (2011)

Pruritus after discontinuation of cetirizine
por: Chung, Amy H., et al.
Publicado: (2019)

Cetirizine modifies quality of life and symptoms in children with seasonal allergic rhinitis: a pilot study
por: Benazzo, Marco, et al.
Publicado: (2021)

Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections
por: Silverstein, Bruce E, et al.
Publicado: (2012)

Recognition of allergic conjunctivitis in patients with allergic rhinitis
por: Williams, Daniel C, et al.
Publicado: (2013)

Y(0.76)Ho(0.24)FeGe(2)O(7): a new member of thortveitite-like layered compounds
por: Rosales, Ivonne, et al.
Publicado: (2009)

Influence of Nb on the Microstructure and Fracture Toughness of (Zr(0.76)Fe(0.24))(100−x)Nb(x) Nano-Eutectic Composites
por: Maity, Tapabrata, et al.
Publicado: (2018)

Characterization of Polybacterial versus Monobacterial Conjunctivitis Infections in Pediatric Subjects Across Multiple Studies and Microbiological Outcomes with Besifloxacin Ophthalmic Suspension 0.6%
por: Blondeau, Joseph M, et al.
Publicado: (2021)

Comparison of levocetirizine pharmacokinetics after single doses of levocetirizine oral solution and cetirizine dry syrup in healthy Japanese male subjects
por: Ino, Hiroko, et al.
Publicado: (2014)

Efficacy of 0.05% epinastine and 0.1% olopatadine for allergic conjunctivitis as seasonal and preseasonal treatment
por: Mizoguchi, Takanori, et al.
Publicado: (2017)

Allergic conjunctivitis in Jos-Nigeria
por: Malu, Keziah N.
Publicado: (2014)

Current Knowledge in Allergic Conjunctivitis
por: Villegas, Beatriz Vidal, et al.
Publicado: (2021)

Therapeutic Targets in Allergic Conjunctivitis
por: Labib, Bisant A., et al.
Publicado: (2022)

Diagnostic approach and grading scheme for canine allergic conjunctivitis
por: Delgado, Esmeralda, et al.
Publicado: (2023)

Poly[[bis(μ-4,4′-bipyridine-κ(2) N:N′)copper(I)] perchlorate 0.24-hydrate]
por: Zhang, Chun-Yan, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_b7bfjpee63lcatgdm5hlio27cc